Vergleich

SARS-CoV-2 (2019-nCoV) Spike RBD-rFc Recombinant Protein Europäischer Partner

ArtNr 40592-V31H-100
Hersteller Sino Biological
Menge 100 ug
Kategorie
Typ Proteins
Specific against other
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Lieferbar
Manufacturer - Category
Protein
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per ug protein as determined by the LAL method.
Activity
Measured by its binding ability in a functional ELISA.
Immobilized human ACE2 protein (His tag) at 2ug/mL (100uL/well) can bind 2019-nCoV Spike Protein (RBD, rabbitFc Tag) (40592-V31H), the EC50 of 2019-nCoV Spike Protein (RBD, rabbitFc Tag)is 2.0-6.0ng/mL.
Protein Construction
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with the Fc region of rabbit IgG1 at the C-terminus.
Expressed Host
HEK293 Cells
Predicted N Terminal
Arg 319
Molecule Mass
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, rabbitFc Tag) consists of 447 amino acids and predicts a molecular mass of 50.3 kDa.
Formulation
Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability and Storage
Samples are stable for up to twelve months from date of receipt at -20C to -80C
Store it under sterile conditions at -20C to -80C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
References
Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen